StocksFin Logo
Global Blood Therapeutics, Inc. country of incorporation
|
|
Dr. Ted Love
|
457 employees
NASDAQ | Healthcare | Biotechnology
BioCryst Pharmaceuticals, Inc. country of incorporation
|
|
Mr. Jon Stonehouse
|
358 employees
NASDAQ | Healthcare | Biotechnology
Q222 reported Aug 8, 2022 Reporting Period
$71.55M 50.5% vs. Q221 Revenues Q222
98.03% -0.4% vs. Q221 Gross Profit Margin
-115.26% ! 21.2% vs. Q221 Net Profit Margin
-44.69M ! -0.8% vs. Q221 Free Cash Flow Q222
$-1.26 ! -12.5% vs. Q221 EPS Q222
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q222
Q322
Q322 reported Nov 4, 2022 Reporting Period
$75.83M 85% vs. Q321 Revenues Q322
95.24% -3.3% vs. Q321 Gross Profit Margin
-56.08% ! 60.9% vs. Q321 Net Profit Margin
-32.62M ! -40.1% vs. Q321 Free Cash Flow Q322
$-0.23 ! 30.3% vs. Q321 EPS Q322
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q222
Q322
Loading...
Loading...
Ratios
As of
Jun 30, 2022
Sep 30, 2022
Quick Ratio
5.88
5.75
Current Ratio
6.88
6.23
Cash Ratio
2.81
3.02
Price to Book
17.71
-9.67
Price to Sales
29.29
30.94
Price to Earnings
-6.35
-13.79